[A18-32] Rurioctocog alfa pegol (haemophilia A) - Benefit assessment according to §35a Social Code Book V
Last updated 15.08.2018
Project no.:
A18-32
Commission:
Commission awarded on 16.05.2018 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Application field:
Haematology
Treatment and prophylaxis of bleeding in patients with haemophilia A (congenital factor VIII deficiency) aged 12 years or older
No study data; added benefit not proven in comparison with the appropriate comparator therapy
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.